Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (71-80 of 508) with videos related to

Pageof 51
Sort By:
European Heart Journal|August 31, 2011
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT studyInger Ekman, Olivier Chassany, Michel Komajda, et al.
European Journal of Heart Failure|May 23, 2013
Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failureJan-Christian Reil, Michele Robertson, Ian Ford, et al.
Stroke|April 20, 2013
Using centrally held data to validate carotid surgery outcome dataWesley P Stuart, Keith K Hussey, Ron K G Eifell, et al.
European Journal of Heart Failure|October 14, 2017
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFTMichael Böhm, Michel Komajda, Jeffrey S Borer, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
European Heart Journal|August 31, 2011
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyJean-Claude Tardif, Eileen O'Meara, Michel Komajda, et al.
Lancet (London, England)|August 31, 2010
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Neurology|August 25, 2017
Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting TrialHugh S Markus, Susanna C Larsson, Wilhelm Kuker, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Archives of Internal Medicine|June 30, 2010
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participantsKausik K Ray, Sreenivasa Rao Kondapally Seshasai, Sebhat Erqou, et al.
Pageof 51

Showing results (71-80 of 508) with videos related to

Sort By:
Pageof 51
European Heart Journal|August 31, 2011
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT studyInger Ekman, Olivier Chassany, Michel Komajda, et al.
European Journal of Heart Failure|May 23, 2013
Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failureJan-Christian Reil, Michele Robertson, Ian Ford, et al.
Stroke|April 20, 2013
Using centrally held data to validate carotid surgery outcome dataWesley P Stuart, Keith K Hussey, Ron K G Eifell, et al.
European Journal of Heart Failure|October 14, 2017
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFTMichael Böhm, Michel Komajda, Jeffrey S Borer, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
European Heart Journal|August 31, 2011
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyJean-Claude Tardif, Eileen O'Meara, Michel Komajda, et al.
Lancet (London, England)|August 31, 2010
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Neurology|August 25, 2017
Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting TrialHugh S Markus, Susanna C Larsson, Wilhelm Kuker, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Archives of Internal Medicine|June 30, 2010
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participantsKausik K Ray, Sreenivasa Rao Kondapally Seshasai, Sebhat Erqou, et al.
Pageof 51